One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

Madoka Sakurai, Takayuki Baba, Masayasu Kitahashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Guzel Bikbova, Toshiyuki Oshitari, Shuichi YamamotoDepartment of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, JapanPurpose: To compare the 1-year results of intravit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sakurai M, Baba T, Kitahashi M, Yokouchi H, Kubota-Taniai M, Bikbova G, Oshitari T, Yamamoto S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8e93214175844ade9d7de490597f2dd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e93214175844ade9d7de490597f2dd7
record_format	dspace
spelling	oai:doaj.org-article:8e93214175844ade9d7de490597f2dd72021-12-02T04:56:23ZOne-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy1177-5483https://doaj.org/article/8e93214175844ade9d7de490597f2dd72014-01-01T00:00:00Zhttp://www.dovepress.com/one-year-results-of-intravitreal-ranibizumab-combined-with-reduced-flu-a15639https://doaj.org/toc/1177-5483 Madoka Sakurai, Takayuki Baba, Masayasu Kitahashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Guzel Bikbova, Toshiyuki Oshitari, Shuichi YamamotoDepartment of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, JapanPurpose: To compare the 1-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy (RF-PDT) to intravitreal ranibizumab (IVR) alone for eyes with polypoidal choroidal vasculopathy (PCV).Methods: We reviewed the medical records from 47 consecutive patients with PCV (47 naïve eyes). Seventeen eyes from 17 patients had one IVR treatment combined with RF-PDT followed by two additional IVR treatments (combined group), and 30 eyes from 30 patients were treated with 3 monthly IVR treatments (IVR group). All eyes had a follow-up period of at least 12 months.Results: At 12 months, the mean logarithm of the minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) significantly improved from 0.55 to 0.38 logMAR units in the combined group (P=0.041) but did not change significantly in the IVR group (P=0.371). The central foveal thickness (CFT) was significantly thinner in both groups at 6 months (P<0.01). Additional IVR injections were required less frequently in the combined group (n=3; 17%) than in the IVR group (n=16; 53%) during the 12 month follow-up (P=0.029).Conclusion: The IVR and RF-PDT combination led to significant BCVA improvements and required fewer additional IVR treatments for at least 12 months in eyes with PCV.Keywords: intravitreal ranibizumab, reduced-fluence photodynamic therapy, polypoidal choroidal vasculopathySakurai MBaba TKitahashi MYokouchi HKubota-Taniai MBikbova GOshitari TYamamoto SDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 235-241 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Sakurai M Baba T Kitahashi M Yokouchi H Kubota-Taniai M Bikbova G Oshitari T Yamamoto S One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
description	Madoka Sakurai, Takayuki Baba, Masayasu Kitahashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Guzel Bikbova, Toshiyuki Oshitari, Shuichi YamamotoDepartment of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, JapanPurpose: To compare the 1-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy (RF-PDT) to intravitreal ranibizumab (IVR) alone for eyes with polypoidal choroidal vasculopathy (PCV).Methods: We reviewed the medical records from 47 consecutive patients with PCV (47 naïve eyes). Seventeen eyes from 17 patients had one IVR treatment combined with RF-PDT followed by two additional IVR treatments (combined group), and 30 eyes from 30 patients were treated with 3 monthly IVR treatments (IVR group). All eyes had a follow-up period of at least 12 months.Results: At 12 months, the mean logarithm of the minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) significantly improved from 0.55 to 0.38 logMAR units in the combined group (P=0.041) but did not change significantly in the IVR group (P=0.371). The central foveal thickness (CFT) was significantly thinner in both groups at 6 months (P<0.01). Additional IVR injections were required less frequently in the combined group (n=3; 17%) than in the IVR group (n=16; 53%) during the 12 month follow-up (P=0.029).Conclusion: The IVR and RF-PDT combination led to significant BCVA improvements and required fewer additional IVR treatments for at least 12 months in eyes with PCV.Keywords: intravitreal ranibizumab, reduced-fluence photodynamic therapy, polypoidal choroidal vasculopathy
format	article
author	Sakurai M Baba T Kitahashi M Yokouchi H Kubota-Taniai M Bikbova G Oshitari T Yamamoto S
author_facet	Sakurai M Baba T Kitahashi M Yokouchi H Kubota-Taniai M Bikbova G Oshitari T Yamamoto S
author_sort	Sakurai M
title	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
title_short	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
title_full	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
title_fullStr	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
title_full_unstemmed	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
title_sort	one-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/8e93214175844ade9d7de490597f2dd7
work_keys_str_mv	AT sakuraim oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT babat oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT kitahashim oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT yokouchih oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT kubotataniaim oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT bikbovag oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT oshitarit oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy AT yamamotos oneyearresultsofintravitrealranibizumabcombinedwithreducedfluencephotodynamictherapyforpolypoidalchoroidalvasculopathy
_version_	1718400964151476224

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

Ejemplares similares